Evidence map›Paper›PMID 38623384›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Cognitive and functional performance and plasma biomarkers of early Alzheimer's disease in Down syndrome.

Emily K Schworer, Benjamin L Handen, Melissa Petersen, Sid O'Bryant, Jamie C Peven, Dana L Tudorascu, Laisze Lee, Sharon J Krinsky-McHale, Christy L Hom, Isabel C H Clare and 13 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Blood-based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  3. Review
  4. Article
  5. Development of Molecular Neuropathology in Down Syndrome across the Lifespan.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  6. Review
  7. Age and sex are associated with Alzheimer's disease neuropathology in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. The Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS): A 10-year report.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  12. Risk of Alzheimer's disease in Down syndrome: Insights gained by multi-omics.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  13. Longitudinal investigation of gait and Alzheimer's disease in adults with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 2 countries.

Emily K SchworerWaisman Center University of Wisconsin-Madison Madison Wisconsin USA.ORCID https://orcid.org/0000-0002-5309-339X
Benjamin L HandenDepartment of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
Melissa PetersenDepartment of Family Medicine and Institute for Translational Research University of North Texas Health Science Center Fort Worth Texas USA.
Sid O'BryantDepartment of Family Medicine and Institute for Translational Research University of North Texas Health Science Center Fort Worth Texas USA.
Jamie C PevenDepartment of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
Dana L TudorascuDepartment of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
Laisze LeeDepartment of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
Sharon J Krinsky-McHaleNew York State Institute for Basic Research in Developmental Disabilities Staten Island New York USA.
Christy L HomDepartment of Psychiatry and Human Behavior University of California Irvine California USA.
Isabel C H ClareDepartment of Psychiatry University of Cambridge Cambridge UK.
Bradley T ChristianWaisman Center University of Wisconsin-Madison Madison Wisconsin USA.
Nicole SchupfTaub Institute for Research on Alzheimer's Disease and the Aging Brain Sergievsky Center and Department of Neurology Vagelos College of Physicians and Surgeons Columbia University New York New York USA.
Joseph H LeeTaub Institute for Research on Alzheimer's Disease and the Aging Brain Sergievsky Center and Department of Neurology Vagelos College of Physicians and Surgeons Columbia University New York New York USA.
Elizabeth HeadDepartment of Pathology & Laboratory Medicine University of California Irvine School of Medicine Irvine California USA.
Mark MapstoneDepartment of Neurology University of California Irvine School of Medicine Irvine California USA.
Ira LottDepartment of Neurology University of California Irvine School of Medicine Irvine California USA.
Beau M AncesDepartment of Neurology Washington University at St. Louis St. Louis Missouri USA.
Shahid ZamanDepartment of Psychiatry University of Cambridge Cambridge UK.
Adam M BrickmanTaub Institute for Research on Alzheimer's Disease and the Aging Brain Sergievsky Center and Department of Neurology Vagelos College of Physicians and Surgeons Columbia University New York New York USA.
Florence LaiDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
H Diana RosasDepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Sigan L HartleyWaisman Center University of Wisconsin-Madison Madison Wisconsin USA.
Alzheimer Biomarker Consortium‐Down Syndrome
University of California, Irvine · USUniversity of Pittsburgh · USColumbia University · USUniversity of Wisconsin–Madison · USHarvard University · USUniversity of Cambridge · GBUniversity of North Texas · USNew York State Office for People With Developmental Disabilities · USWashington University in St. Louis · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI O'BRYANT, SID E · 2020 to 2025
$103.7M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, JAMES T. · 1985 to 2019
$43.0M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI AMY J. KIND · 2019 to 2026
$34.5M
NCATS NIH HHS UL1 TR001414NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002373NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066519NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS R01 AG070028NIA NIH HHS U01 AG051406NIA NIH HHS U01 AG051412NIA NIH HHS U19 AG068054NIA NIH HHS U24 AG021886NICHD NIH HHS P50 HD105353NICHD NIH HHS T32 HD007489NICHD NIH HHS U54 HD087011NICHD NIH HHS U54 HD090256
6 · The paper itself

Abstract

introductionPeople with Down syndrome (DS) have a 75% to 90% lifetime risk of Alzheimer's disease (AD). AD pathology begins a decade or more prior to onset of clinical AD dementia in people with DS. It is not clear if plasma biomarkers of AD pathology are correlated with early cognitive and functional impairments in DS, and if these biomarkers could be used to track the early stages of AD in DS or to inform inclusion criteria for clinical AD treatment trials.

methodsThis large cross-sectional cohort study investigated the associations between plasma biomarkers of amyloid beta (Aβ)42/40, total tau, and neurofilament light chain (NfL) and cognitive (episodic memory, visual-motor integration, and visuospatial abilities) and functional (adaptive behavior) impairments in 260 adults with DS without dementia (aged 25-81 years).

resultsIn general linear models lower plasma Aβ42/40 was related to lower visuospatial ability, higher total tau was related to lower episodic memory, and higher NfL was related to lower visuospatial ability and lower episodic memory. DISCUSSION: Plasma biomarkers may have utility in tracking AD pathology associated with early stages of cognitive decline in adults with DS, although associations were modest. Highlights: Plasma Alzheimer's disease (AD) biomarkers correlate with cognition prior to dementia in Down syndrome.Lower plasma amyloid beta 42/40 was related to lower visuospatial abilities.Higher plasma total tau and neurofilament light chain were associated with lower cognitive performance.Plasma biomarkers show potential for tracking early stages of AD symptomology.

Indexed as

adaptive behavioradultscognitive performancefunctional abilitiesneurofilament light chainplasma amyloid betaplasma total tautrisomy 21

Identifiers

PMID38623384
PMCPMC11016818
OpenAlexW4394797991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.